Vectus Biosystems Share Price and Company Fundamentals
Last traded: Today at 2:37 AM
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that improves speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was founded in 2005 and is based in Rosebery, Australia.
|Primary activities||Medical research and development. Phase I human trials for anti-fibrotic drug VB0004.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||3-11 Primrose Avenue Rosebery NSW 2018 Australia|
|Phone / Fax||61 2 9662 4144 / 61 2 9662 6040|
|Share registry||BOARDROOM PTY LIMITED|
Vectus Biosystems paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.VBS dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
VBS's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of Aug 2022, following are the company executives and directors listed on Vectus Biosystems.
|Dr. Karen Annette Duggan||CEO & Exec. Director||223.88k|
|Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin||Company Sec.|
|Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC||Consultant|
Profitability and management effectiveness
Return on assets
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Vectus Biosystems is and its enterprise value is .
The VBS's stocks Beta value is 0.62 making it 38% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Vectus Biosystems (VBS)
Vectus Biosystems (ASX:VBS) Frequently Asked Questions
1. What is Vectus Biosystems's Stock Symbol?
Vectus Biosystems trades on ASX under the ticker symbol "VBS".
2. What is Vectus Biosystems's stock price today?
One share of VBS stock can currently be purchased for approximately $0.9.
3. How can I contact Vectus Biosystems?
Vectus Biosystems's mailing address is 3-11 Primrose Avenue Rosebery NSW 2018 Australia. The company can be reached via phone at 61 2 9662 4144.
4. What is Vectus Biosystems's official website?
The official website of Vectus Biosystems is https://www.vectusbiosystems.com.au.
5. Which share registry manages Vectus Biosystems's stock?
Vectus Biosystems's stock is managed by BOARDROOM PTY LIMITED.